IP Library Granted Patent US 12678496
Granted Patent B2
US 12678496 · App. 18/018,316 · Granted Jul 14, 2026

Gold nanoparticle intranasal vaccine compositions

Inventors: Tarik F. Massoud (Stanford, CA); Ramasamy Paulmurugan (Stanford, CA); Uday Sukumar (Stanford, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A61K39/12A61P31/14A61K2039/55505A61K2039/55555B82Y5/00B82Y30/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678496
App. No.
18/018,316
Granted
Jul 14, 2026
Kind
B2
Abstract

Provided herein, inter alia, are complexes comprising nanoparticles attached to viral proteins or nucleic acids encoding said viral proteins. Methods for making and using said complexes are provided. Compositions including the complexes are contemplated to be useful for treating and/or preventing viral infections.

Claims (9)

1 . An intranasal vaccine composition comprising complexes of:

(a) a nanoparticle consisting of a gold core coated with an outer layer consisting of a uniform monolayer of a cationic polysaccharide, wherein the cationic polysaccharide is chitosan and

the outer layer is covalently attached to the gold core; and

(b) a nucleic acid encoding a SARS-CoV-2 S protein, wherein the nucleic acid is attached to said nanoparticle and

(c) a pharmaceutically acceptable excipient,

wherein the complexes are from about 20 nm to about 80 nm in diameter.

2 . The complex of claim 1 , comprising a plurality of nucleic acids encoding said pulmonary viral protein or fragment thereof.

3 . A method of treating or preventing a pulmonary viral disease in a subject, the method comprising intranasal administration of the pharmaceutical composition of claim 1 to the subject.

4 . A method of immunizing a subject susceptible to a pulmonary viral disease, the method comprising intranasal administration of the pharmaceutical composition of claim 1 to the subject.